All In Biotech

NDA 203137 · Ge Healthcare

Vizamyl

Flutemetamol F-18 · Intravenous · Radioactive Diagnostic Agent

Novel

Last checked: Nov 20, 2026Latest source record: Jun 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Oct 25, 2013

Approved uses

2

Original approval plus efficacy supplements

Registered trials

9

1 Phase 3, 1 recruiting

FAERS reports

520

166 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 6, 2026.

VIZAMYL is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products VIZAMYL is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products ( 1 )

Mechanism: Flutemetamol F 18 binds to amyloid beta plaques in the brain and the F 18 isotope produces a positron signal that is detected by a PET scanner. In in vitro binding studies using postmortem human brain homogenates containing fibrillar amyloid beta, the dissociation constant (Kd) for flutemetamol was 6.7 nM. Selectivity of 3 H-flutemetamol binding in postmortem human brain sections was demonstrated using autoradiography, silver-stained protein, and immunohistochemistry (monoclonal antibody to amyloid beta) correlation studies.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VIZAMYL · FLUTEMETAMOL F-18 121.5mCi/30ML (4.05mCi/ML) · INJECTABLE, INTRAVENOUS · Prescription
  • VIZAMYL · FLUTEMETAMOL F-18 40.5mCi/10ML (4.05mCi/ML) · INJECTABLE, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Flutemetamol F-18" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • flushing265
  • dyspnoea140
  • back pain120
  • dizziness91
  • nausea87
  • chest discomfort62
  • headache51
  • chest pain46
  • cough39
  • erythema39
  • feeling hot37
  • hot flush29

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20174
20187
201913
20207
20217
20227
202315
202476
2025199
2026185

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Ge Healthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.